In this article, we will discuss 12 Best Future Stocks to Buy Right Now.

Future stocks are some of Wall Street’s most exciting investments because they offer exposure to businesses expected to compound earnings far faster than the broader market. Billionaire investors and hedge fund managers often debate on valuations, but many agree on one central principle: earnings growth is what ultimately drives stock prices over time.

Legendary hedge fund investor Stanley Druckenmiller has repeatedly argued that investors should focus on companies entering major growth inflection points, particularly when earnings are accelerating faster than consensus expectations. Druckenmiller has often favored businesses benefiting from secular megatrends like artificial intelligence, cloud computing, semiconductors, and digital infrastructure, saying that explosive earnings growth can justify premium valuations when a company is early in a powerful cycle.

Ken Griffin has also emphasized that technology, data infrastructure, and productivity-enhancing businesses remain major long-term growth themes, although he warns investors not to blindly chase momentum when valuations disconnect from fundamentals. Meanwhile, Ray Dalio argues that growth investing works best when investors understand macroeconomic risks, liquidity cycles, and competitive durability, not simply headline EPS forecasts.

Recent studies strongly support the case for investing in future high-growth stocks. Research from JPMorgan Asset Management found that AI, productivity gains, and earnings expansion remain major drivers of equity returns in 2026, with strategists arguing that strong profit growth could push markets significantly higher over the next year. Meanwhile, recent market data cited by UBS Global Wealth Management showed that the firm raised its 2026 S&P 500 EPS estimate to $335, representing about 20% year-over-year earnings growth, while increasing its index target on expectations of continued profit expansion.

The investment case is simple: future stocks with high 5-year EPS forecasts often benefit from compounding earnings growth, operating leverage, innovation leadership, and investor willingness to pay premium valuations for future cash flows.

With this context in mind, here are some of the best future stocks to buy right now.

Our Methodology

We sifted through financial media reports to find stocks with multi-year growth opportunities. We then selected stocks that are expected to grow their earnings by at least 25% over the next 5 years, and limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds. To make the list easier to navigate, we ranked the stocks in ascending order of their forecasted earnings growth.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

12 Best Future Stocks to Buy Right Now

12. Eli Lilly and Company (NYSE:LLY)

Five-Year EPS Forecast: 28.38%

On May 21, Eli Lilly and Company (NYSE:LLY) reported pivotal Phase 3 data for retatrutide that demonstrated weight loss of up to 26.1% at 80 weeks and more than 30% at 104 weeks in higher-BMI participants, while also delivering broad improvements across key cardiometabolic risk markers. Wolfe Research described the results as setting a new benchmark in next-generation obesity therapeutics, noting that the data further strengthens Lilly’s leadership and differentiation within the rapidly expanding GLP-1 market, while reiterating an Outperform rating and $1,350 price target on the shares.

A day earlier, Engage Biologics announced that it had been acquired by Eli Lilly and Company (NYSE:LLY). Engage is developing the Tethosome platform, a non-viral DNA delivery technology designed to address longstanding challenges in DNA delivery, including potency, tolerability, and repeat dosing. Lilly agreed to acquire the company for up to $202 million in cash, consisting of an upfront payment and additional milestone-based payments tied to development progress, expanding its pipeline and reinforcing its commitment to next-generation drug delivery innovation.

Eli Lilly and Company (NYSE:LLY) is a global pharmaceutical leader focused on the research, development, and manufacturing of innovative medicines. The company concentrates on major therapeutic areas, including diabetes, obesity, immunology, oncology, and neuroscience, positioning itself at the forefront of some of the fastest-growing segments in healthcare. It is headquartered in Indianapolis, Indiana, and was founded in 1876.

11. CrowdStrike Holdings, Inc. (NASDAQ:CRWD)

Five-Year EPS Forecast: 29.02%

On May 21, CrowdStrike Holdings, Inc. (NASDAQ:CRWD) announced a new integration with Claude’s Compliance API, bringing Claude Enterprise and Claude Platform activity into the CrowdStrike Falcon platform to provide centralized visibility, detection, response, and governance for enterprise AI usage. The integration allows activity data from Claude’s Compliance API to flow into Falcon Next-Gen SIEM and Charlotte Agentic SOAR, making AI-related activity part of CrowdStrike’s broader security dataset and enabling organizations to extend existing security operations to AI environments at scale.

The day before, Morgan Stanley analyst Meta Marshall raised the firm’s price target on CrowdStrike Holdings, Inc. (NASDAQ:CRWD) to $610 from $510 while maintaining an Overweight rating. The firm cited healthy demand trends across the Falcon platform, highlighting strong competitive positioning in SIEM, growing interest in AI-driven detection and response, and continued momentum in large enterprise deals, signaling sustained commercial traction across key cybersecurity categories.

CrowdStrike Holdings, Inc. (NASDAQ:CRWD) is a leading cloud-native cybersecurity and threat intelligence company specializing in endpoint protection, cloud security, identity security, and next-generation SIEM solutions through its Falcon platform. The company has established itself as a key player in enterprise cybersecurity by leveraging artificial intelligence and data-driven threat intelligence to protect digital environments at scale. It is headquartered in Austin, Texas, and was founded in 2011.